Clinical Trials · NCT02338960
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Palatin Technologies, Inc
- Enrollment
- 714
- Start date
- Jan 2015
- Locations
- 91 sites, United States, Canada
- Primary endpoint
- Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.